Optimized synthesis of a per-O-methylated β-cyclodextrin dimer linked at the secondary face by a pyridine ligand

In a previous study, we reported a 1:1 complex (hemoCD) of 5,10,15,20-tetrakis(4-sulfonatophenyl)porphinatoiron(II) (Fe(II)TPPS) with per- O -methylated β-cyclodextrin (CD) dimer having a pyridine (Py) linker, which was able to bind O 2 and CO reversibly in aqueous solution. Among the CD dimers synt...

Full description

Saved in:
Bibliographic Details
Published inJournal of inclusion phenomena and macrocyclic chemistry Vol. 93; no. 1-2; pp. 67 - 76
Main Authors Mao, Qiyue, Kitagishi, Hiroaki
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 15.02.2019
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In a previous study, we reported a 1:1 complex (hemoCD) of 5,10,15,20-tetrakis(4-sulfonatophenyl)porphinatoiron(II) (Fe(II)TPPS) with per- O -methylated β-cyclodextrin (CD) dimer having a pyridine (Py) linker, which was able to bind O 2 and CO reversibly in aqueous solution. Among the CD dimers synthesized by us, the CD dimer (Py3OCD) that was linked via ether bonds at 3,3′-positions formed the best inclusion complex with Fe(II)TPPS and was utilized as an artificial O 2 carrier and an antidote for cyanide anion poisoning. For practical applications, considerable amounts of Py3OCD need to be synthesized. However, the experimental conditions for the synthesis of Py3OCD have not been optimized as yet and an unidentified byproduct is sometimes obtained in the dimerization step. In this study, we identified the byproduct as the per- O -methylated CD dimer linked at the 6,6′-positions of two CDs. It was found that the undesired 6,6′-dimer was formed when the reaction temperature in the dimerization reaction was over 80 °C. This finding led us to effectively synthesize a large amount of Py3OCD in good yield, which is helpful for the practical use of hemoCD as an artificial O 2 carrier or an antidote for cyanide anion.
ISSN:1388-3127
1573-1111
DOI:10.1007/s10847-018-0839-4